A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.
The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.
More...
FDA staff note deaths in Pfizer bone drug study
One of the strictest abortion bans in the country will be on the ballot this November...
Martha Lillard, who contracted polio at age five and spent most of her life dependent on...
One in four Israelis now engages in harmful substance use as the psychological fallout from Israel’s...
New York City’s famed Solomon R Guggenheim Museum was among a number of Manhattan buildings that...
